Science-based regulation of endocrine disrupting chemicals in Europe: which approach?

This is the author's manuscript

Original Citation:
Science-based regulation of endocrine disrupting chemicals in Europe: which approach? / Bourguignon, Jean-Pierre; Slama, Rémy; Bergman, Åke; Demeneix, Barbara; Ivell, Richard; Kortenkamp, Andreas; Panzica, Giancarlo; Trasande, Leonardo; Zoeller, R Thomas. - In: THE LANCET DIABETES & ENDOCRINOLOGY. - ISSN 2213-8587. - 4:8(2016), pp. 643-646.

Availability:
This version is available http://hdl.handle.net/2318/1616903 since 2017-05-14T14:30:09Z

Published version:
DOI:10.1016/S2213-8587(16)30121-8

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Identifying Chemicals That Disrupt Hormone Systems And Threaten Health: The Right Approach Keeps Refinement Possible

Jean-Pierre Bourguignon¹, Rémy Slama², Åke Bergman³, Barbara Demeneix⁴, Richard Ivell⁵, Andreas Kortenkamp⁶, GianCarlo Panzica⁷, Leonardo Trasande⁸ and R. Thomas Zoeller⁹

¹ Pediatric Endocrinology, CHU Liège and Neuroendocrinology Unit, GIGA Neurosciences, Univ. Liège, Belgium; ²Insenm, CNRS and Univ. Grenoble Alpes, IAB joint research center (IAB, U1209), Team of Environmental Epidemiology, Grenoble, France; ³Swedish Toxicology sciences research center (Swetox), Södertälje, Sweden; ⁴UMR CNRS/MNHN 7221, Dept. RDDM, Muséum National d'Histoire Naturelle, 75005 Paris, France; ⁵School of Biosciences & School of Veterinary Medicine and Science, University of Nottingham, UK; ⁶Brunel University London, Institute of Environment, Health and Societies, Uxbridge, UK; ⁷Dept. Neuroscience, University of Torino, and Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy; ⁸Departments of Pediatrics, Environmental Medicine and Population Health, New York University School of Medicine, New York, New York, USA; ⁹University of Massachusetts, Biology Department, Amherst, Massachusetts, USA

Corresponding author: JP Bourguignon, University of Liège, GIGA Neurosciences, Bât. B36 Tour 4 +1, Avenue de l’Hôpital, 1, B4000 Liège, Belgium. Tel: +32 4 366 2539 email: jpbourguignon@ulg.ac.be

Endocrine disruptors (EDs) are defined by the World Health Organization (WHO) as “exogenous compounds or mixtures that alter function(s) of the endocrine system and consequently cause adverse effects in an intact organism, or its progeny, or (sub)populations” (1). European laws on pesticides (Plant protection products regulation, PPPR) and biocide products regulation (BPR), enacted in 2009 and 2012, respectively, place restrictions on the use of active substances with severe forms of toxicity, including carcinogenicity, mutagenicity, reproductive toxicity and endocrine disruption. Chemicals with such properties will in future not receive authorization for placement on the market as active substances in pesticide or biocide products. Compared to earlier EU law, these legal provisions are innovative in two respects: for the first time, pesticides and biocides with endocrine disrupting properties are regulated; secondly, these severe toxicities are regulated solely on the basis of hazard identification, and not risk assessment, as previously. This requires that scientific criteria for the identification of endocrine disrupters (EDs) are developed, and the European Commission (EC) was obliged by law to publish such scientific criteria within the context of PPPR and BPR, by 2013.
Chemical industries have strongly lobbied against “hazard-based cut-off” criteria for EDs and succeeded in convincing the EC to conduct an impact assessment before defining the ED criteria (2). Inevitably, this has delayed the process to such an extent that Sweden and other EU Member States brought a case against the EC. In December 2015, the European Court of Justice judged that the EC acted unlawfully in failing to publish the criteria, and that an impact assessment was not necessary for their development (3).

To this day (May 2016), the EC has not published the ED criteria and continues to justify this delay with reference to a controversy within the scientific community (4). However, we have recently shown that the “controversy” is not about the basics of ED science, but is the result of a confusion of risk assessment and hazard identification (5). Very recently, this confusion was resolved, and a consensus among the scientists engaged in the previous disputes has emerged (6). We also demonstrated that EDs can be identified using a scientific strategy analogous to that implemented for carcinogens by the International Agency for Research on Cancer (IARC) (5). Accordingly, no one would suggest making the definition of carcinogens dependent on an impact assessment study, as should apply to EDs.

Whilst a great deal is known about how hormones affect health and disease, there remains much to learn. Similarly, we know a great deal about how some manufactured chemicals can cause adverse effects in humans, farm animals and wildlife by interfering with hormones (7). Recent research demonstrates that EDs can produce epigenetic modifications and transgenerational effects (8). This is honest science that must be considered appropriately for its implications for human health today and for future generations. Robust science at the leading edge allows us to discriminate among the known, the possible and the unknown. Therefore, the decision taken by the EC should be based on what we know now, and allow for incorporating new information as it becomes available.

In its 2014 impact assessment, the EC has proposed a roadmap with four different options for defining regulatory ED criteria (9). The first one does not provide defining criteria, and is therefore not operable. Two options (labelled 2 and 3) both rely on WHO definition of EDs; option 2 defines a single category of EDs, while option 3 further identifies suspected endocrine disruptors and endocrine active substances (Fig. 1A). Such categories based on level of evidence are consistent with those used in the EU for carcinogens, mutagens and reprotoxicants, which are hazards of equivalent concern to EDs. An assessment of the strength of the evidence has also been used in studies on the cost of managing health consequences of EDs in the EU. With more than 99% probability, this cost exceeds 160 billion Euros per year (10). Moreover, option 3 provides the necessary characteristics that will allow for incorporation of new data as it becomes available which might trigger revised categorizations (Fig. 1A). The responders to the public consultation initiated by the EC about ED identification criteria made no mistake about it since the vast majority selected option 3 (11). The Endocrine Society, the world’s largest organization devoted to research on hormones and the clinical care of endocrine disorders, also supports option 3.
The last option (option 4, Fig. 1B) uses a binary definition (ED or non-ED) and incorporates potency as a criterion. The idea of including potency was initiated by UK and German authorities. Mindful of the potential economic impact on industry of regulating substances with ED properties in a hazard-based system, the stated intention was to regulate only the “worst offenders” (12). Potency, however, is not mentioned in the accepted WHO definition (1) and has been deemed irrelevant to identify EDs (5). Potency is actually quite complex to apply as a criterion and scientifically indefensible because a single chemical may appear differently potent depending on the endpoint and the testing conditions (Fig. 1B). Potency is measured by a dose-response function; however, the variability of “response” and the corresponding likelihood of overlooking effects is what makes “potency” so complicated. Historically, diethylstilbestrol (DES) and thalidomide provide examples. These drugs were prescribed for pregnant women without any adverse effects being observed in these women. However, the children of treated women showed adverse effects – either at the time of birth, or several years later. In these cases, the prediction of negligible potency from some in vivo testing gave physicians the confidence to prescribe these drugs but was tragically missing developmental issues. In a recent position statement about EU regulation of EDs, the Endocrine Society also recommended to exclude potency from identification criteria (13). Similarly, the recent consensus statement from the scientists engaged in the previous disputes states that potency considerations have no place in the hazard identification process of ED properties (6).

The current scientific consensus on the relevance of the WHO definition of EDs (1), the irrelevance of potency for the identification of EDs (5, 6) and the inapplicability of impact assessment studies to provide scientific definition of EDs (5, 13) all support our conclusion as scientists: science provides all necessary arguments towards implementation of relevant criteria to identify EDs. Such criteria are actually consistent with an option already formulated by the European Commission (option 3 of the EC roadmap). Public health urgently deserves science-based regulations.

Declaration of interests:
The authors have no conflicts of interest other than BD who is cofounder of the company WatchFrog.

Acknowledgments
JPB, RS, BD, RI, GCP, LT and RTZ thank the Endocrine Society for organizational support and reimbursement of travel expenses related to meetings about incorporation of endocrine science data in regulatory management of EDCs.

References


Figure 1. In a 2014 roadmap, the EC has proposed criteria for ED identification through four options, two of which being schematically represented in panel A (option 3) and panel B (option 4). By this summer 2016, EDs will be identified based on one option or the other. Option 3 identifies endocrine inactive substances and three ED categories based on the level of evidence. It allows for further revision using new scientific information. Option 4 uses potency as a criterion and identifies only one ED category. Its application implies further questions about selected endpoints, cut-off criteria and predictive value. In panel B, the 4 symbols arbitrarily denote different levels of potency of a given chemical depending on the studied endpoint.